Bio-Rad Laboratories (BIO-B) Cash from Investing Activities (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Cash from Investing Activities data on file, last reported at -$93.2 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$93.2 million, down 3313.79% year-over-year; the trailing twelve-month figure through Mar 2026 was -$285.8 million (down 150.26% YoY), and the FY2025 annual result was -$189.7 million, down 18.41% from the prior year.
• Cash from Investing Activities declined to -$93.2 million in Q1 2026 per BIO-B's latest filing, from -$34.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $72.2 million in Q4 2023 and troughed at -$916.1 million in Q1 2022.
• A 5-year average of -$95.9 million and a median of -$43.1 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities surged 223.28% in 2023, then slumped 3313.79% in 2026.
• A 5-year view of Cash from Investing Activities shows it stood at -$58.6 million in 2022, then surged by 223.28% to $72.2 million in 2023, then tumbled by 142.25% to -$30.5 million in 2024, then declined by 12.13% to -$34.2 million in 2025, then tumbled by 172.51% to -$93.2 million in 2026.
• Business Quant data shows BIO-B's Cash from Investing Activities at -$93.2 million in Q1 2026, -$34.2 million in Q4 2025, and -$43.0 million in Q3 2025.